CN103889407B - 用于甲状腺素运载蛋白相关的淀粉样变性的疗法 - Google Patents

用于甲状腺素运载蛋白相关的淀粉样变性的疗法 Download PDF

Info

Publication number
CN103889407B
CN103889407B CN201280051812.8A CN201280051812A CN103889407B CN 103889407 B CN103889407 B CN 103889407B CN 201280051812 A CN201280051812 A CN 201280051812A CN 103889407 B CN103889407 B CN 103889407B
Authority
CN
China
Prior art keywords
comt
inhibitor
ttr
group
methyltransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280051812.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103889407A (zh
Inventor
马克·桑德拉斯卡萨多
劳尔·因萨博罗纳特
努利亚·雷格博拉诺
努利亚·加瓦尔巴塔拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Som Innovation Biotech SA
Original Assignee
Som Innovation Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47076222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103889407(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Som Innovation Biotech SA filed Critical Som Innovation Biotech SA
Publication of CN103889407A publication Critical patent/CN103889407A/zh
Application granted granted Critical
Publication of CN103889407B publication Critical patent/CN103889407B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201280051812.8A 2011-10-24 2012-10-23 用于甲状腺素运载蛋白相关的淀粉样变性的疗法 Expired - Fee Related CN103889407B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382326.4 2011-10-24
EP11382326 2011-10-24
PCT/EP2012/070945 WO2013060668A1 (en) 2011-10-24 2012-10-23 New therapy for transthyretin-associated amyloidosis

Publications (2)

Publication Number Publication Date
CN103889407A CN103889407A (zh) 2014-06-25
CN103889407B true CN103889407B (zh) 2017-03-15

Family

ID=47076222

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280051812.8A Expired - Fee Related CN103889407B (zh) 2011-10-24 2012-10-23 用于甲状腺素运载蛋白相关的淀粉样变性的疗法

Country Status (19)

Country Link
US (5) US9610270B2 (enExample)
EP (1) EP2770988B1 (enExample)
JP (1) JP6068484B2 (enExample)
KR (1) KR102017354B1 (enExample)
CN (1) CN103889407B (enExample)
AU (2) AU2012327275B2 (enExample)
BR (1) BR112014009322B1 (enExample)
CA (1) CA2852808C (enExample)
CL (1) CL2014000893A1 (enExample)
CY (1) CY1118151T1 (enExample)
ES (1) ES2593038T3 (enExample)
IL (1) IL231907B (enExample)
MX (2) MX385516B (enExample)
PL (1) PL2770988T3 (enExample)
PT (1) PT2770988T (enExample)
RU (2) RU2747536C2 (enExample)
SG (2) SG10201609933WA (enExample)
WO (1) WO2013060668A1 (enExample)
ZA (1) ZA201402546B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6068484B2 (ja) * 2011-10-24 2017-01-25 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法
KR102410072B1 (ko) * 2014-08-29 2022-06-20 알닐람 파마슈티칼스 인코포레이티드 트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
EP3275433A1 (en) 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
AU2019236469A1 (en) * 2018-03-12 2020-10-08 Corino Therapeutics, Inc. Combination therapy for TTR amyloidosis
MX2021014682A (es) * 2019-05-31 2022-04-06 Plex Pharmaceuticals Inc Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
WO2022104383A1 (en) * 2020-11-13 2022-05-19 Plex Pharmaceuticals, Inc. Pharmacological agents for treating conditions of the eye
CN114324693B (zh) * 2022-01-14 2023-01-13 大连博源医学科技有限公司 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法
EP4601624A2 (en) * 2022-10-10 2025-08-20 Corino Therapeutics, Inc. Modified release tolcapone formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1921856A (zh) * 2004-02-20 2007-02-28 诺瓦提斯公司 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂
CN1953746A (zh) * 2004-03-05 2007-04-25 细胞基因公司 用于治疗和控制中枢神经系统疾病的包含选择性细胞因子抑制药的组合物和使用方法
CN101198598A (zh) * 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
PT1372682E (pt) 2001-03-15 2012-08-03 Proteotech Inc Catequinas para o tratamento de fibrilogénese em doença de alzheimer, doença de parkinson, amiloidose αa sistémica e outras perturbações amiloides
CN1688299A (zh) 2002-01-29 2005-10-26 普罗特米克斯公司 抑制细胞毒性蛋白构象异构体
KR20060124712A (ko) 2004-02-20 2006-12-05 노파르티스 아게 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제
ES2339790T3 (es) 2004-08-30 2010-05-25 Seo Hong Yoo Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
GB2429645A (en) 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
US20120016037A1 (en) 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
GB0718718D0 (en) 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
DE102010010572A1 (de) 2010-03-08 2011-09-08 Mahle International Gmbh Trockenseparator
JP6068484B2 (ja) * 2011-10-24 2017-01-25 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1921856A (zh) * 2004-02-20 2007-02-28 诺瓦提斯公司 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂
CN1953746A (zh) * 2004-03-05 2007-04-25 细胞基因公司 用于治疗和控制中枢神经系统疾病的包含选择性细胞因子抑制药的组合物和使用方法
CN101198598A (zh) * 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity;Saviana Di Giovanni et al;《JOURNAL OF BIOLOGICAL CHEMISTRY》;20100514;第285卷(第２０期);14941-14954 *

Also Published As

Publication number Publication date
PT2770988T (pt) 2016-09-05
MX2014004863A (es) 2014-05-27
IL231907B (en) 2018-05-31
SG10201609933WA (en) 2017-02-27
RU2747536C2 (ru) 2021-05-06
BR112014009322B1 (pt) 2022-05-10
ES2593038T3 (es) 2016-12-05
US10786473B2 (en) 2020-09-29
RU2017119539A3 (enExample) 2020-06-29
CN103889407A (zh) 2014-06-25
AU2012327275A2 (en) 2014-04-17
BR112014009322A8 (pt) 2018-01-16
MX385516B (es) 2025-03-18
US9610270B2 (en) 2017-04-04
US20200138760A1 (en) 2020-05-07
NZ623267A (en) 2015-11-27
US20140296188A1 (en) 2014-10-02
MX347784B (es) 2017-05-12
RU2014114930A (ru) 2015-12-10
US10045956B2 (en) 2018-08-14
US20170304243A1 (en) 2017-10-26
AU2012327275A1 (en) 2014-04-17
US11564899B2 (en) 2023-01-31
CY1118151T1 (el) 2017-06-28
RU2017119539A (ru) 2018-11-09
US10449169B2 (en) 2019-10-22
KR20140090161A (ko) 2014-07-16
WO2013060668A1 (en) 2013-05-02
AU2017202670A1 (en) 2017-05-11
PL2770988T3 (pl) 2017-01-31
US20190091188A1 (en) 2019-03-28
RU2623062C2 (ru) 2017-06-21
HK1198432A1 (en) 2015-04-24
CA2852808C (en) 2021-07-06
SG11201401215VA (en) 2014-08-28
BR112014009322A2 (pt) 2017-04-18
AU2017202670B2 (en) 2019-06-06
KR102017354B1 (ko) 2019-09-02
CA2852808A1 (en) 2013-05-02
AU2012327275B2 (en) 2017-03-02
JP6068484B2 (ja) 2017-01-25
CL2014000893A1 (es) 2014-09-05
IL231907A0 (en) 2014-05-28
ZA201402546B (en) 2015-07-29
EP2770988A1 (en) 2014-09-03
US20200390733A1 (en) 2020-12-17
JP2014530842A (ja) 2014-11-20
EP2770988B1 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
US11564899B2 (en) Therapy for transthyretin-associated amyloidosis
JP7242945B2 (ja) 細胞生存率を向上させるための組成物およびその使用方法
JP2021006552A (ja) アルツハイマー病と関連疾患の治療のための併用療法
JP2005500346A (ja) タウフィラメント形成重合を阻害するかまたは逆転させる方法
US20210069139A1 (en) Stabilization of transthyretin tetramers in biological fluids
HK1198432B (en) Therapy for transthyretin-associated amyloidosis
Alcaín et al. Coenzyme Q and Age-Related Neurodegenerative Disorders: Parkinson and Alzheimer Diseases
NZ623267B2 (en) New therapy for transthyretin-associated amyloidosis
WO2014155184A1 (en) Treatment for parkinson's disease
FR3063643A1 (fr) Prevention des risques associes a un allongement de l'intervalle qt d'origine medicamenteuse a l'aide d'un inhibiteur specifique de la production de ros d'origine mitochondriale
HK1162993A (en) Combination of angiotension receptor blockers (arb) and nsaids for use in ameliorating cachexia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1198432

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1198432

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170315